Comparative cost-effectiveness of ribociclib and palbociclib as first-line treatment for HR+/HER2- advanced breast cancer in postmenopausal women: analysis from a Medicare perspective.

Loading papers...

Comparative cost-effectiveness of ribociclib and palbociclib as first-line treatment for HR+/HER2- advanced breast cancer in postmenopausal women: analysis from a Medicare perspective. | InnScience